Government policies make Canada’s pharmaceutical environment less attractive to drug companies.
new drug regulations
In 2017, the federal government introduced new regulations for the drug review board.
Advanced clinical trials in Canada, which were consistent between 2015 and 2019, decreased by 26 per cent in 2020.
New drugs are approved later in Canada than in the United States and European Union.
Forcing manufacturers of high-cost drugs to reduce their prices by up to 80 per cent is unsustainable.
Developing and testing new drugs costs a lot of money.